Skip to main content

3 Result(s)

within Henry E. Mark Remove this filter

and

  1. No Access

    Article

    Opportunities and challenges following approval of resmetirom for MASH liver disease

    The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health ...

    Jeffrey V. Lazarus, Dana Ivancovsky Wajcman, Henry E. Mark… in Nature Medicine (2024)

  2. Article

    Advancing the global public health agenda for NAFLD: a consensus statement

    Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-rang...

    Jeffrey V. Lazarus, Henry E. Mark… in Nature Reviews Gastroenterology & Hepatolo… (2022)

    Download PDF (2295 KB) View Article

  3. No Access

    Article

    Defining comprehensive models of care for NAFLD

    Non-alcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease globally. Despite the increased demand placed on health-care systems, little attention has been given to the design a...

    Jeffrey V. Lazarus, Quentin M. Anstee… in Nature Reviews Gastroenterology & Hepatolo… (2021)